Secukinumab for children with psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 17 years old and weigh at least 10 kg (about 22 lbs).
- Diagnosed with juvenile psoriatic arthritis for at least 6 months.
- Must have at least 3 swollen or painful joints at the start of the study.
- Have tried an NSAID (like ibuprofen) for 1 month or a DMARD (like methotrexate) for 2 months without success, or couldn't tolerate them.
- Cannot have active inflammatory bowel disease, active uveitis (eye inflammation), or another type of arthritis besides psoriatic arthritis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
This study looks at how well secukinumab, a biologic medicine, works over the long term for children and teenagers with two types of juvenile arthritis: psoriatic arthritis (which also involves skin psoriasis) and enthesitis-related arthritis (which causes pain where tendons meet bones). It uses data from a German registry to see if the treatment is effective and safe in real-world settings.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
Hear when a new Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.